Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cellsTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyCyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesotheliomaCombined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor modelVirally-directed fluorescent imaging (VFI) can facilitate endoscopic staging.Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12Delivery of antiangiogenic agents for cancer gene therapy.Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbitsVirus-based therapies for colon cancer.Herpes simplex virus 1 (HSV-1) for cancer treatment.Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Trial watch: Oncolytic viruses for cancer therapyTargeting tumor vasculature through oncolytic virotherapy: recent advances.Advances in oncolytic virus therapy for glioma."Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.HSV Recombinant Vectors for Gene Therapy.Advance in herpes simplex viruses for cancer therapy.Update on oncolytic viral therapy - targeting angiogenesisEvolution of oncolytic viruses: novel strategies for cancer treatment.Development of a squamous cell carcinoma mouse model for immunotoxicity testing.Adenovirus-mediated interferon-γ gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo.Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice.Interleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy.Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
P2860
Q24596171-3DA30C5A-808D-477D-849D-1F44838FEEE2Q24618562-545C0EA4-93D3-4C20-AC75-F79AB761FBCEQ27021951-BC87223E-85A3-45B1-8376-FF390273FE22Q28072347-EDB27167-9E61-47FB-957A-5C9EA3B928BEQ33641230-75467805-B749-4793-9556-A2540B1FCC8AQ33670645-BE059AF8-5BAC-4571-B46B-AE83FADF1073Q34275711-C6A0417E-D4C0-445E-A68F-D0E243ED5187Q34411569-BC6657FC-11CA-4D4E-8E63-EAF9BD96C023Q34427459-CE41BD3B-8994-4CBC-9868-DC61CF6EE32AQ34536549-821A1C31-2AF8-4669-A82D-B9B8E8D49472Q35943736-F09FBF88-25D3-42E0-82A3-833EB3DEC21BQ36200143-6EE0E00C-FB4A-4D44-821D-1DCBCCCC4651Q36315458-F278A5D1-B89D-4982-A07B-68C31CEF2DB5Q36327069-7235DEF0-3131-4ABA-A1EF-3206E85D1A80Q36444443-8819DB67-57FB-4FF3-B013-28DE70E395B5Q36879211-4CC7BDB7-6BDE-46F6-ACFC-33CD66688D5DQ37028023-039725A0-4C6A-410B-8C47-E3165AEFD5B8Q37031932-D9FDB265-7549-4FD0-BBBD-86360B5FD91BQ37287118-FE664AE9-F1CE-490D-B17B-F56F9A37EDDEQ37622288-D7C7C1C7-7F19-4466-B4CA-8EC6E656F150Q37787777-379D0528-99B8-452D-8C17-3D63F53AAAD8Q38096940-03446B71-88B5-44CA-8C40-5E265549B9A9Q38128561-6BF4820A-11FF-415B-827E-630300946AE7Q38159802-626D73A7-69B2-4B7F-855C-A8F70FF8F6B3Q38871984-5DC8AF4A-9B59-4B33-BA5A-AE5D336B98C3Q39196158-D7E7D997-2E5B-4E43-B796-BE07C657F95AQ39247534-9BB702A2-B7E6-49ED-BC8D-7162AE10FCAFQ39402703-DF6A0638-2AAC-4D8D-9129-DAA00D8A0FB9Q41906680-9A8AD56B-C659-4D50-A4F3-50B75043670CQ41948724-A2A37B09-4279-48CE-80A1-7D4F19A7B881Q45360866-84921B80-2814-42CA-8764-D6C5C1B8FFB6Q45423758-09A49201-A1FC-4FA9-B992-07CFA9379941
P2860
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
@en
type
label
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
@en
prefLabel
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
@en
P2093
P1476
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
@en
P2093
Bhuvanesh Singh
Brendon M Stiles
Mei-Ki Chan
Prasad S Adusumilli
Richard J Wong
Ronald A Ghossein
Zhenkun Yu
P304
P356
10.1158/1078-0432.CCR-04-0081
P407
P577
2004-07-01T00:00:00Z